BBBianca Belei

Bianca Belei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bianca Belei has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Ileana Enatescu

    Discipline of Neonatology, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania

    2 shared publications
  • Laura Olariu

    First Pediatric Clinic, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timișoara, Romania

    2 shared publications
  • Oana Belei

    First Pediatric Clinic, Disturbances of Growth and Development on Children Research Center, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timișoara, Romania

    2 shared publications
  • Roxana Folescu

    Department of Balneology, Medical Recovery and Rheumatology, Family Medicine University Clinic, Center for Preventive Medicine, Center for Advanced Research in Cardiovascular Pathology and Hemostaseology, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania

    2 shared publications
  • Adina Teodora Crăciun

    Third Pediatric Clinic, “Louis Țurcanu” Emergency Children Hospital, 300041 Timișoara, Romania

    1 shared publication
  • Adrian Goldiș

    Department of Gastroenterology and Hepatology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania

    1 shared publication

Latest Publications

  • Open Access

    Machine Learning-Based Prediction of Treatment Response to Vitamin D3 in Adolescents and Young Adults with Inflammatory Bowel Disease: A Prospective, Open-Label, Alternation-Based Comparative Study

    by Marina Adriana Mercioni, Adrian Goldiș, Nina Holban, Mihai Vasile Popescu, Radu Dragomir, Christian Goldiș, Bianca Belei, Ileana Enatescu, Roxana Folescu, Laura Olariu, et al.

    Background: Chronic inflammatory bowel diseases (IBDs), specifically Crohn’s disease and ulcerative colitis, present substantial clinical challenges characterized by a relapsing-remitting course. These conditions often lead to serious complications and significantly impair nutritional status, physical development, and overall quality of life. Methods: This unicentric, prospective, open-label, alternation-based comparative study investigated the efficacy of vitamin D3 supplementation in adolescents with IBD. Patients aged 15–25 years were randomly assigned to receive either 1000 IU/day or 2000 IU/day of cholecalciferol for 6 months as an adjuvant to standard care. Eighty patients completed the study. Results: By month 6, remission was achieved in 52.5% of patients receiving 1000 IU/day (Group A) and 87.5% of those receiving 2000 IU/day (Group B). Significant differences were observed between groups regarding disease activity (p = 0.007), C-reactive protein levels (30.17 ± 15.74 mg/L vs. 62.82 ± 37.14 mg/L; p < 0.001), and fecal calprotectin levels. Conclusions: The machine learning models demonstrated consistent performance in assessing inflammatory indicators, with a weighted average recall exceeding 72% (Random Forest: 82.50%). No adverse effects were reported. Supplementation with 2000 IU/day of vitamin D3 for 6 months was associated with more favorable clinical and biochemical outcomes than 1000 IU/day in this single-center open-label study as an adjunct to standard treatment in adolescents and young adults with IBD. The results suggest that higher doses of vitamin D may be beneficial in achieving remission and reducing systemic inflammation.

  • Open Access

    Gut Microbiota Alterations and Dysbiosis Patterns in Pediatric Inflammatory Bowel Disease: Clinical Correlations and Therapeutic Impact

    by Anda-Maria Beca, Roxana Folescu, Adina Teodora Crăciun, Laura Olariu, Ileana Enatescu, Bianca Belei, Oana Belei

    Background: Gut microbiota alterations are increasingly recognized as key contributors to the development and clinical course of inflammatory bowel disease (IBD), particularly in pediatric patients, in whom microbial maturation and immune regulation are still evolving. Objective: This study aimed to assess intestinal microbiota composition and dysbiosis severity in pediatric IBD, with comparative analyses according to disease phenotype (Crohn’s disease versus ulcerative colitis) and therapeutic strategy (biologic versus non-biologic treatment). Methods: A prospective cohort of 60 pediatric patients diagnosed with IBD based on Porto criteria was evaluated. Fecal samples were obtained at baseline and after three months of combined standard IBD treatment and adjunct microbiota-targeted therapy, and were analyzed using an AI-assisted microbiota profiling platform. A semi-quantitative dysbiosis score was calculated based on the relative abundance of proinflammatory taxa and depletion of short-chain fatty acid (SCFA)-producing bacteria. Microbial parameters were correlated with clinical and therapeutic variables, including the Organism of Interest metric and the Gut Microbiota Index (GMI). Results: Dysbiosis severity was significantly higher in patients with Crohn’s disease compared with ulcerative colitis (9.65 ± 1.44 vs. 8.42 ± 1.88, p = 0.037). Patients receiving biologic therapy showed a trend toward lower dysbiosis scores and improved microbial indices, although statistical significance was not reached. Severe dysbiosis was identified in 46.7% of the cohort. Strong positive correlations were observed between the dysbiosis score, Organism of Interest metric and GMI (r = 0.68–0.72, p < 0.01). Conclusions: Pediatric IBD is associated with a reproducible dysbiotic profile, more pronounced in Crohn’s disease and partially modulated by biologic therapy. The observed correlations between microbiota-derived indices support their potential utility as complementary markers of intestinal microbial imbalance and disease activity.